Black Diamond Therapeutics, Inc. (BDTX) Financial Analysis & Valuation | Quarter Chart
Black Diamond Therapeutics, Inc. (BDTX)
BDTXPrice: $2.17
Fair Value: 🔒
🔒score
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epiderma... more
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes me... more
Description
Shares
| Market Cap | $123.35M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mark A. Velleca |
| IPO Date | 2020-01-31 | CAGR | — |
| Employees | 24 | Website | www.blackdiamondtherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BDTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $132.81M | P/E Ratio | 16.21 |
| Forward P/E | -2.49 | PEG Ratio | — |
| P/S Ratio | 1.76 | P/B Ratio | 1.1 |
| P/CF Ratio | 4.17 | P/FCF Ratio | 4.17 |
| EPS | $0.24 | EPS Growth 1Y | -129.92% |
| EPS Growth 3Y | -115.08% | EPS Growth 5Y | -118.54% |
| Revenue Growth 1Y | inf% | Gross Margin | 1% |
| Operating Margin | 0.28% | Profit Margin | 0.32% |
| ROE | 0.17% | ROA | 0.16% |
| ROCE | 0.16% | Current Ratio | 8.42 |
| Quick Ratio | 8.42 | Cash Ratio | 1.33 |
| Debt/Equity | 0.13 | Interest Coverage | — |
| Altman Z Score | -0.09 | Piotroski Score | 6 |